Verition Fund Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-40,590
| Closed | -$6.9M | – | 2934 |
|
|
2025
Q4 | $6.9M | Buy |
40,590
+13,291
| +49% | +$2.04M | 0.03% | 662 |
|
|
2025
Q3 | $3.6M | Sell |
27,299
-5,397
| -17% | -$647K | 0.01% | 1486 |
|
|
2025
Q2 | $3.47M | Sell |
32,696
-219,783
| -87% | -$23.9M | 0.02% | 1476 |
|
|
2025
Q1 | $31.3M | Buy |
252,479
+239,319
| +1,819% | +$31.2M | 0.15% | 111 |
|
|
2024
Q4 | $1.62M | Buy |
+13,160
| New | +$1.55M | 0.01% | 1704 |
|
|
2024
Q1 | – | Sell |
-3,737
| Closed | -$460K | – | 2874 |
|
|
2023
Q4 | $460K | Buy |
+3,737
| New | +$466K | ﹤0.01% | 1556 |
|
|
2023
Q2 | – | Sell |
-10,330
| Closed | -$1.51M | – | 2381 |
|
|
2023
Q1 | $1.51M | Buy |
10,330
+8,324
| +415% | +$1.23M | 0.02% | 797 |
|
|
2022
Q4 | $320K | Sell |
2,006
-2,368
| -54% | -$347K | 0.01% | 1469 |
|
|
2022
Q3 | $583K | Buy |
4,374
+2,956
| +208% | +$449K | 0.01% | 1787 |
|
|
2022
Q2 | $221K | Sell |
1,418
-49,712
| -97% | -$7.65M | ﹤0.01% | 1886 |
|
|
2022
Q1 | $7.96M | Buy |
51,130
+8,954
| +21% | +$1.3M | 0.1% | 212 |
|
|
2021
Q4 | $5.37M | Buy |
42,176
+11,313
| +37% | +$1.49M | 0.04% | 329 |
|
|
2021
Q3 | $4.02M | Buy |
+30,863
| New | +$4.66M | 0.03% | 344 |
|
|
2020
Q2 | – | Sell |
-2,801
| Closed | -$279K | – | 1111 |
|
|
2020
Q1 | $279K | Buy |
2,801
+1,187
| +74% | +$153K | 0.01% | 442 |
|
|
2019
Q4 | $241K | Buy |
+1,614
| New | +$220K | ﹤0.01% | 896 |
|
|
2019
Q3 | – | Sell |
-12,690
| Closed | -$1.81M | – | 1186 |
|
|
2019
Q2 | $1.81M | Sell |
12,690
-136
| -1% | -$18.3K | 0.05% | 262 |
|
|
2019
Q1 | $1.83M | Buy |
12,826
+7,453
| +139% | +$972K | 0.07% | 229 |
|
|
2018
Q4 | $666K | Sell |
5,373
-10,336
| -66% | -$1.53M | 0.05% | 362 |
|
|
2018
Q3 | $2.64M | Sell |
15,709
-7,583
| -33% | -$1.3M | 0.09% | 211 |
|
|
2018
Q2 | $4.01M | Buy |
23,292
+3,014
| +15% | +$493K | 0.25% | 75 |
|
|
2018
Q1 | $3.06M | Buy |
+20,278
| New | +$2.97M | 0.23% | 78 |
|
|
2017
Q3 | – | Sell |
-12,600
| Closed | -$1.96M | – | 1278 |
|
|
2017
Q2 | $1.96M | Buy |
+12,600
| New | +$1.93M | 0.19% | 93 |
|
|
2017
Q1 | – | Sell |
-7,036
| Closed | -$767K | – | 1326 |
|
|
2016
Q4 | $767K | Buy |
+7,036
| New | +$784K | 0.07% | 363 |
|
|
2016
Q3 | – | Sell |
-16,789
| Closed | -$2.37M | – | 1219 |
|
|
2016
Q2 | $2.37M | Buy |
+16,789
| New | +$2.47M | 0.3% | 60 |
|
|
2015
Q3 | – | Sell |
-12,152
| Closed | -$2.14M | – | 629 |
|
|
2015
Q2 | $2.14M | Buy |
12,152
+4,992
| +70% | +$897K | 0.38% | 46 |
|
|
2015
Q1 | $1.24M | Buy |
+7,160
| New | +$1.23M | 0.14% | 44 |
|
|
2013
Q3 | – | Sell |
-4,557
| Closed | -$313K | – | 621 |
|
|
2013
Q2 | $313K | Buy |
+4,557
| New | +$279K | 0.06% | 340 |
|
Other funds holding JAZZ
VPM
VCM
EC
Verition Fund Management's JAZZ Position: Q1 2026 in Review
Verition Fund Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 40,590 shares — an estimated $6.9M sold.
Verition Fund Management first reported a position in JAZZ in Q2 2013 and held it in 27 quarters. The position peaked at $31.3M in Q1 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Verition Fund Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Verition Fund Management sold 40,590 Jazz Pharmaceuticals shares in Q1 2026, an estimated $6.9M.
- Verition Fund Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Verition Fund Management's Jazz Pharmaceuticals position peaked at $31.3M in Q1 2025.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.